NOVATO, Calif.–(BUSINESS WIRE)–Zenni Optical, a leader for more than a decade in online prescription eyewear, announces today the launch of its Metropolitan Collection. Featuring 14 classic eyewear styles remastered for modern lifestyles, the Metropolitan Collection is inspired by the visionaries who bring form, function and sophistication to America’s great cities. The frames in the Metropolitan Collection start at just $35.95 which include single-vision prescription lenses, and are availabl
WASHINGTON–(BUSINESS WIRE)–Imagine watching a 3D movie on your smart phone and suddenly getting a headache or even feeling nauseous. Such viewer discomfort is one of the biggest obstacles preventing widespread application of 3D display technology – especially for portable devices whose slim design poses an extra challenge. Now researchers at the Sun Yan-Sen University, China have developed a new display with comfortable 3D visual effects. The device is based on a “super multi-view technique”
スイス・ヌーシャテル–(BUSINESS WIRE)–（ビジネスワイヤ） — Swiss Advanced Vision (SAV-IOL SA – www.sav-iol.com)は、医療分野で競合相手が存在しない製品の発売を発表しました。水晶体摘出後の白内障治療が適応の眼内レンズ（IOL）であるInFo Instant Focus©は、患者がまるで20歳の時のように完全な視覚を回復させます。 InFoが開発される以前は、白内障手術の2つの転帰が眼科にとって常に問題となっていました。すなわち老眼の矯正（近見視力の改善）と解像能力（鮮明な像知覚）です。また現在利用可能なソリューションはすべて、脳が天然レンズの代替物に適応するまで数週間を必要としています。それに加えて、多焦点レンズは通常、ゴースト像やハローが発生します。 InFoは解像能力を妨げることなく即座に視力を矯正できる初のインプラントです。InFoは光物理学に基づいて、一定強度を持つ単一のライトフィールドを独自に利用しています。どのような状況であれ、完全に鮮明な像が網膜に映し出されます。脳は焦点の増加によって混乱すること
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its fourth quarter and year end 2015 financial results will be released after the market closes on Tuesday, March 1, 2016. Following the release, Aerie will…
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved the initiation of a dividend policy under which the Company will target a cash dividend to the Company’s stockholders in the amount of $0.16 per share per annum, payable in equal quarterly installments. The Company’s Board of Directors also declared an initial quarterly cash dividend of $0.04 per share of common stock, payable on March 24, 2016 to stockholders of record a
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the RBC Capital Markets Healthcare Conference on Wednesday, February 24, 2016.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the Phase 3 clinical d…
PALO ALTO, Calif.–(BUSINESS WIRE)–Please replace the release dated February 11, 2016 with the following corrected version due to multiple revisions. The corrected release reads: MEDIA ALERT: CSIRO TO HOST SILICON VALLEY INNOVATION SUMMIT & SHOWCASE Australia’s Scientific and Research Organization Will Highlight New Breakthroughs and Outline Roadmap for Collaboration with Silicon Valley Technology Community CSIRO, the scientific and research organization for Australia responsible for the b
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/g5lftv/prescriptionrx) has announced the addition of the “Prescription/Rx Sunglass Market Analysis By Lens Material (Glass, CR-39, Polycarbonate, Polyurethane) An…
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (“Second Sight” or “the Company”) (Nasdaq:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, today announced the publication of a positive 3-year FLORA study in the Australian journal Clinical And Experimental Optometry for the Argus® II Retinal Prosthesis System (“Argus II”). The Functional Low-Vision Observer Rated Assessment (FLORA), a multi-part
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2015 financial results after the market close on Tuesday, March 1, 2016. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/hc7wft/pharmapoint_dry) has announced the addition of the “PharmaPoint: Dry Eye Syndrome – Global Drug Forecast and Market Assessment to 2024” report to their off…
FRIDOLFING, Germany–(BUSINESS WIRE)–Press Kit Materials are Available at: http://www.tradeshownews.com/events/mobile-world-congress-2016/Rosenberger-Hochfrequenztechnik/ Company: Rosenberger Hochfrequenztechnik Booth/Stand: 6G37 Event: Mobile World Congress 2016Feb 22 – 25, 2016Barcelona, ES Web: http://www.rosenberger.com Facebook: https://www.facebook.com/Rosenberger.HFT About Rosenberger Hochfrequenztechnik Rosenberger is one of the worldwide leading suppliers of controlled impedance and
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its fourth quarter ended December 31, 2015. Bruker’s revenues for the fourth quarter of 2015 were $478.2 million, a decline of 5.9 percent compared to revenues of $508.0 million in the fourth quarter of 2014. Excluding a 0.6 percent net negative effect from acquisitions & divestitures, and a 7.8 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-ye
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced promising results in diabetic retinopathy from the company’s phase 2a study (“TIME-2”) of its lead candidate, AKB-9778, a first-in-class Tie2 activator. AKB-9778, dosed at 15 mg BID subcutaneously, alone and in combination with Lucentis® (ranibizumab injection dosed at 0.3 mg intravitreally), improved underlying retinopathy according to
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (“Second Sight” or “the Company”) (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced that Dr. Robert Greenberg, Chairman, and Will McGuire, President and Chief Executive Officer, will host one-on-one meetings and present at the following conferences this month: Conference: RBC Capital Markets 2016 Global Healthcare Confere
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has established a direct sales organization and launched the iStent inject® Trabecular Micro-Bypass Stent in Australia. The iStent inject is approved by the Australian Therapeutics Goods Administration for use in conjunctio
TOKIO–(BUSINESS WIRE)–PENTAX Medical, una división del grupo HOYA, ha anunciado el nombramiento de Gerald W. Bottero como presidente global de PENTAX Medical con fecha de 1 de febrero de 2016. «El grupo HOYA se alegra de contar con Gerald W. Bottero al frente de la división global de PENTAX Medical», comunicó Hiroshi Suzuki, presidente y CEO del grupo HOYA. «Bottero aporta vastos conocimientos, sabiduría y experiencia de los diferentes puestos ejecutivos que ha desempeñado en HOYA, especialme
TOKIO–(BUSINESS WIRE)–PENTAX Medical, ein Geschäftsbereich der HOYA Group, hat die Ernennung von Gerald W. Bottero zum Global President von PENTAX Medical ab dem 1.Februar 2016 bekannt gegeben. „Die HOYA Group freut sich, Gerald W. Bottero als Führungskraft für die Global Division von PENTAX Medical gewonnen zu haben“, sagt Hiroshi Suzuki, President und CEO der HOYA Group. „Herr Bottero bringt umfangreiche Kenntnisse, Verständnis und Erfahrung aus seinen verschiedenen Funktionen in der Untern
TOKYO–(BUSINESS WIRE)–PENTAX Medical, filiale du Groupe HOYA, a annoncé la nomination de Gerald W. Bottero au poste de Président Mondial de PENTAX Medical à compter du 1er février 2016. « Le Groupe HOYA a le plaisir d’accueillir Gerald W. Bottero à la tête de la division internationale de PENTAX Medical », a déclaré Hiroshi Suzuki, Président-Directeur Général du Groupe HOYA. « M. Bottero a occupé plusieurs postes de direction internationale au sein du Groupe HOYA, et saura mettre à profit les